Whole Blood Clot Lysis: Enhanced by Exposure to Autologous but not to Homologous Plasma

 

PDF Download Buy Article Permissions and Reprints

Summary

A new phenomenon is described: Whole blood clots lyse faster in the plasma of the same donor than in another donor’s plasma. We have confirmed this finding in 68 healthy volunteers by a standardized, pairwise analysis and have found a mean difference in clot weights of 8.8 ± 0.99% (SEM, p<0.0001) after 6 h of urokinase-induced (200 U/ml) clot lysis. Nu difference was found in a group of 7 pairs of identical twins. Further analysis revealed that increasing concentrations of platelets in the plasma reduced the difference significantly but did not abolish it. A 1:1 mixture of autologous with homologous plasma reduced the autologous advantage by almost 50%, thus making an inhibitor unlikely. The absence of cellular components in clots of platelet- poor plasma resulted in the loss of the advantage after 2 h of lysis, but not in the early phase. We conclude that there is a clear advantage of autologous over homologous clot lysis. Potential mechanisms are discussed and include an increased affinity of enzymes for their substrates in a given individual.

• References

• 1 Loren M, Garcia Frade LJ, Torrado MC, Navarro JL. Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thromb Res 1989; 56: 67-75
  CrossrefPubMedGoogle Scholar
• 2 Carroll RC, Gerrard JM, Gilliam JM. Clot retraction facilitates clot lysis. Blood 1981; 57: 44-8
  PubMedGoogle Scholar
• 3 Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and nonfibrin specific plasminogen activators. Thromb Haemost 1989; 62: 1083-7
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Sabovic M, Lijnen HR, Keber D, Collen D. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb Haemost 1990; 64: 450-4
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42
  CrossrefPubMedGoogle Scholar
• 6 Deguchi K, Murashima S, Shirakawa S, Soria C, Soria J, Dunn F, Tobelem G. The potentiating effect of platelet on plasminogen activation by tissue plasminogen activator. Thromb Res 1985; 40: 853-61
  CrossrefPubMedGoogle Scholar
• 7 Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation 1989; 79: 920-8
  CrossrefPubMedGoogle Scholar
• 8 Knox P, Crooks S. Plasminogen activation and lysis of blood clots induced by cells in vitro. J Cell Physiol 1988; 135: 467-73
  CrossrefPubMedGoogle Scholar
• 9 Miles LA, Plow EF, Plasminogen receptors. Ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988; 2: 61-71
  PubMedGoogle Scholar
• 10 Ronne E, Behrendt N, Ellis V, Ploug M, Dano K, Hoyer-Hansen G. Cell- induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH₂-terminal domain of the urokinase receptor. Fed Europ Biochem Soc lett 1991; 288: 233-6
  PubMedGoogle Scholar
• 11 Gaffney PJ, Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res 1979; 14: 85-94
  CrossrefPubMedGoogle Scholar
• 12 Jansen JW, Haverkate F, Koopman J, Nieuwenhuis HK, Kluft C, Boschman TA. Influence of factor XHIa activity on human whole blood clot lysis in vitro. Thromb Haemost 1987; 57: 171-5
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 McDonagh RP, McDonagh J, Duckert F. The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis. Brit J Haematol 1971; 21: 323-32
  CrossrefPubMedGoogle Scholar
• 14 Aoki N, Moroi M, Matsuda M, Tachiya K. The behavior of α₂-plasmin inhibitor in fibrinolytic states. J Clin Invest 1977; 60: 361-9
  CrossrefPubMedGoogle Scholar
• 15 Ichinose A, Tamaki T, Aoki N. Factor XHI-mediated cross-linking of NH₂- terminal peptide of α₂-plasmin inhibitor to fibrin. Fed Europ Biochem Soc 1983; 153: 369-71
  PubMedGoogle Scholar
• 16 Reed GL, 3^rd Matsueda GR, Haber E. Inhibition of clot-bound α₂-antiplasmin enhances in vivo thrombolysis. Circulation 1990; 82: 164-8
  CrossrefPubMedGoogle Scholar
• 17 Sakata Y, Eguchi A, Mimuro J, Matsuda M, Sumi Y. Clot lysis induced by a monoclonal antibody against α₂-plasmin inhibitor. Blood 1989; 74: 2692-7
  CrossrefPubMedGoogle Scholar
• 18 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partal characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-72
  CrossrefPubMedGoogle Scholar
• 19 Kruithof EK, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-13
  PubMedGoogle Scholar
• 20 Mosher DF, Misenheimer TM, Stenflo J, Hogg PJ. Modulation of fibrinolysis by thrombospondin. Ann NY Acad Sci 1992; 667: 64-9
  CrossrefPubMedGoogle Scholar
• 21 De Fouw NJ, Haverkate F, Bertina RM, Koopman J, van Wijngaarden A, van Hinsbergh VW. The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro. Blood 1986; 67: 1189-92
  PubMedGoogle Scholar
• 22 Taylor Jr FB, Lockhart MS. Whole blood clot lysis: in vitro modulation by activated protein C. Thromb Res 1985; 37: 639-49
  CrossrefPubMedGoogle Scholar
• 23 Ploug M, Plesner T, Ronne E, Ellis V, Hoyer-Hansen G, Ebbe Hansen N, Dano K. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992; 79: 1447-55
  PubMedGoogle Scholar
• 24 Eisenberg PR, Jaffe AS, Stump DC, Collen D, Bovill EG. Validity of enzyme-linked immunosorbent assay of cross-linked fibrin degradation products as a measure of clot lysis. Circulation 1990; 82: 1159-68
  CrossrefPubMedGoogle Scholar
• 25 Kahn MB, Palmer S, Marlar RA, Fink L. A modified quantitative whole blood clot lysis method for general laboratory analysis of fibrinolysis. Thromb Res 1990; 59: 171-81
  CrossrefPubMedGoogle Scholar
• 26 Comp PC, Jacocks RM, Taylor FB Jr. The dilute whole blood clot lysis assay: a screening method for identifying postoperative patients with a high incidence of deep venous thrombosis. J Lab Clin Med 1979; 93: 120-7
  PubMedGoogle Scholar
• 27 Beer JH, Klay HP, Haberli A, Herren T, Straub PW. Advantage of autologous over homologous plosma in whole blood clot lysis; platelets can reduce the effect. Thromb Haemost 1991; 65: 1267a (abstr.)
  PubMedGoogle Scholar
• 28 Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: Effects on the activation of plasminogen. Biochemistry 1986; 25: 4033-40
  CrossrefPubMedGoogle Scholar
• 29 Carroll RC, Radcliffe RD, Taylor Jr FB, Gerrard JM. Plasminogen, plasminogen activator and platelets in the regulation of clot lysis. J Lab Clin Med 1982; 100: 986-96
  PubMedGoogle Scholar
• 30 Sakata Y, Aoki N. Significance of cross-linking of α₂-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42
  CrossrefPubMedGoogle Scholar
• 31 Gaussem P, Gandrille S, Molho-Sabatier P, Capron L, Fiessinger JN, Aiach M. A plasma clot lysis assay based on the release of fibrin degradation products: application to the diagnosis of hypofibrinolytic states. Thromb Haemost 1990; 3: 76-81
  PubMedGoogle Scholar
• 32 Brenner B, Francis CW, Totterman S, Kessler CM, Rao AK, Rubin R, Kwaan HC, Gabriel KR, Mardcr VJ. Quantitation of venous clot lysis wiih the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble librin degradation. Circulation 1990; 81: 1818-25
  CrossrefPubMedGoogle Scholar
• 33 Sundell IB, Nilsso TK, Ranby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age sex, blood pressure and body build measurements: A cross-sectional study in Norsjö Sweden. J Clin Epidemiol 1989; 42: 719-23
  CrossrefPubMedGoogle Scholar
• 34 Holt JC, Niewiarowski S. Secretion of plasminogen by washed human platelets. Circulation 1980; 62 Suppl III-342 (abstr)
  PubMedGoogle Scholar
• 35 Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis 1988; 2: 73-84
  PubMedGoogle Scholar
• 36 Park S, Harker LA, Marzec UM, Levin EG. Demonstration of single chain urokinase type plasminogen activator on the human platelet membrane. Blood 1989; 73: 1421-5
  PubMedGoogle Scholar
• 37 Plow EF, Collen D. The presence and release of alpha₂-antiplasmin from human platelets. Blood 1981; 58: 1069-1974
  PubMedGoogle Scholar
• 38 Leung LL, Harpel PC, Nachman RL, Rabellino EM. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62: 1016-26
  PubMedGoogle Scholar
• 39 Miles LA, Plow EF. Receptor-mediated binding of the fibrinolytic components plasminogen and urokinase to peripheral blood cells. Thromb Haemost 1987; 58: 936-42
  Article in Thieme ConnectPubMedGoogle Scholar
• 40 Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260: 4303-11
  PubMedGoogle Scholar
• 41 Silverstein RL, Friedlander RJ Jr, Nicholas RL, Nachman RL. Binding of lys-plasminogen to monocytes/macrophages. J Clin Invest 1988; 82: 1948-55
  CrossrefPubMedGoogle Scholar
• 42 Behrendt N, Ronne E, Ploug M, Petri T, Lobe D, Nielsen LS, Schleuning WD, Blasi F, Appella E, Dano K. The human receptor for urokinase plasminogen activator. J Biol Chem 1990; 265: 6453-60
  PubMedGoogle Scholar
• 43 Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103: 2411-20
  CrossrefPubMedGoogle Scholar